Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.558
Sell
RSI(14)
38.302
Neutral
STOCH(KDJ)(9,3,3)
67.659
Buy
ATR(14)
2.492
High Vlolatility
CCI(14)
-22.279
Neutral
Williams %R
65.413
Sell
TRIX(12,20)
-1.625
Sell
StochRSI(14)
91.468
Buy
Ultragenyx Pharmaceutical Inc
RARE24.110USD
-0.260-1.07%
Close 01/13, 16:00（ET）Quotes delayed by 15 min
2.33BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Ultragenyx Pharmaceutical Inc
Currency: USD Updated: 2026-01-13Key Insights
Ultragenyx Pharmaceutical Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 53 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 67.60.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Ultragenyx Pharmaceutical Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Ultragenyx Pharmaceutical Inc Highlights
StrengthsRisks
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 54.19% year-on-year.
Overvalued
The company’s latest PE is -4.07, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 100.03M shares, decreasing 2.53% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 59.28K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.41.
Analyst Rating
Based on
21
analysts
Buy
Current Rating
67.600
Target Price
+200.31%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-01-13The current financial score of Ultragenyx Pharmaceutical Inc is 7.46, ranking 113 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 159.93M, representing a year-over-year increase of 14.65%, while its net profit experienced a year-over-year increase of 35.12%.
Score
Financials
4.75
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.24
Operational Efficiency
10.00
Growth Potential
7.98
Shareholder Returns
7.31
Ultragenyx Pharmaceutical Inc's Company Valuation
Currency: USD Updated: 2026-01-13The current valuation score of Ultragenyx Pharmaceutical Inc is 6.12, ranking 133 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -4.07, which is -18.21% below the recent high of -3.33 and -123.52% above the recent low of -9.09.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 53/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-01-13The current earnings forecast score of Ultragenyx Pharmaceutical Inc is 8.57, ranking 24 out of 159 in the Pharmaceuticals industry. The average price target is 78.50, with a high of 128.00 and a low of 35.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
21
analysts
Buy
Current Rating
67.600
Target Price
+200.31%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
Ultragenyx Pharmaceutical Inc
RARE
21
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-01-13The current price momentum score of Ultragenyx Pharmaceutical Inc is 7.11, ranking 69 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 34.48 and the support level at 16.08, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
23.680
Buy
MA10
23.343
Buy
MA20
28.046
Sell
MA50
31.476
Sell
MA100
31.317
Sell
MA200
32.604
Sell
Institutional Confidence
Currency: USD Updated: 2026-01-13The current institutional shareholding score of Ultragenyx Pharmaceutical Inc is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 103.68%, representing a quarter-over-quarter increase of 2.76%. The largest institutional shareholder is The Vanguard, holding a total of 10.11M shares, representing 10.48% of shares outstanding, with 0.67% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
Fidelity Management & Research Company LLC
State Street Investment Management (US)
RTW Investments L.P.
JP Morgan Asset Management
Fidelity Institutional Asset Management
Baker Bros. Advisors LP
Kakkis (Emil D)
1
2
Risk Assessment
Currency: USD Updated: 2026-01-13The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Ultragenyx Pharmaceutical Inc is 3.64, ranking 101 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.16. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.16
VaR
+4.75%
240-Day Maximum Drawdown
+56.92%
240-Day Volatility
+81.83%
Return
Best Daily Return
60 days
+15.52%
120 days
+15.52%
5 years
+15.52%
Worst Daily Return
60 days
-42.32%
120 days
-42.32%
5 years
-42.32%
Sharpe Ratio
60 days
-0.63
120 days
+0.25
5 years
-0.31
Risk Assessment
Maximum Drawdown
240 days
+56.92%
3 years
+66.78%
5 years
+82.96%
Return-to-Drawdown Ratio
240 days
-0.76
3 years
-0.24
5 years
-0.19
Skewness
240 days
-4.07
3 years
-2.86
5 years
-1.85
Volatility
Realised Volatility
240 days
+81.83%
5 years
+58.22%
Standardised True Range
240 days
+6.65%
5 years
+9.90%
Downside Risk-Adjusted Return
120 days
+22.78%
240 days
+22.78%
Maximum Daily Upside Volatility
60 days
+100.57%
Maximum Daily Downside Volatility
60 days
+96.41%
Liquidity
Average Turnover Rate
60 days
+2.10%
120 days
+1.55%
5 years
--
Turnover Deviation
20 days
+41.15%
60 days
+86.34%
120 days
+37.68%
Peer Comparison
Pharmaceuticals
Ultragenyx Pharmaceutical Inc
RARE
7.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
8.93 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.78 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.66 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
ANI Pharmaceuticals Inc
ANIP
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cardinal Health Inc
CAH
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Ultragenyx Pharmaceutical Inc?
The TradingKey Stock Score provides a comprehensive assessment of Ultragenyx Pharmaceutical Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Ultragenyx Pharmaceutical Inc’s performance and outlook.
How do we generate the financial health score of Ultragenyx Pharmaceutical Inc?
To generate the financial health score of Ultragenyx Pharmaceutical Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Ultragenyx Pharmaceutical Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Ultragenyx Pharmaceutical Inc.
How do we generate the company valuation score of Ultragenyx Pharmaceutical Inc?
To generate the company valuation score of Ultragenyx Pharmaceutical Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Ultragenyx Pharmaceutical Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Ultragenyx Pharmaceutical Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Ultragenyx Pharmaceutical Inc.
How do we generate the earnings forecast score of Ultragenyx Pharmaceutical Inc?
To calculate the earnings forecast score of Ultragenyx Pharmaceutical Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Ultragenyx Pharmaceutical Inc’s future.
How do we generate the price momentum score of Ultragenyx Pharmaceutical Inc?
When generating the price momentum score for Ultragenyx Pharmaceutical Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Ultragenyx Pharmaceutical Inc’s prices. A higher score indicates a more stable short-term price trend for Ultragenyx Pharmaceutical Inc.
How do we generate the institutional confidence score of Ultragenyx Pharmaceutical Inc?
To generate the institutional confidence score of Ultragenyx Pharmaceutical Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Ultragenyx Pharmaceutical Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Ultragenyx Pharmaceutical Inc.
How do we generate the risk management score of Ultragenyx Pharmaceutical Inc?
To assess the risk management score of Ultragenyx Pharmaceutical Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Ultragenyx Pharmaceutical Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Ultragenyx Pharmaceutical Inc.
